Contact
searchSearch
HMP Global
Login
Angela Hirbe, MD, PhD
Conference Coverage
Mirdametinib Shows Durable Response in NF1-Associated Plexiform Neurofibromas
12/19/2025
Angela Hirbe, MD, PhD
Angela Hirbe, MD, PhD, discusses updated results from the phase 2b ReNeu trial, which showed that mirdametinib demonstrates durable and deep volumetric response in adult and pediatric patients with NF1-associated plexiform neurofibromas not...
Angela Hirbe, MD, PhD, discusses updated results from the phase 2b ReNeu trial, which showed that mirdametinib demonstrates durable and deep volumetric response in adult and pediatric patients with NF1-associated plexiform neurofibromas not...
Angela Hirbe, MD, PhD, discusses...
12/19/2025
Oncology
News
Vorasidenib Added to Temozolomide Shows Favorable Safety in IDH1/2-Mutated Gliomas
12/05/2025
Stephanie Holland
Findings from a phase 1b trial show the addition of 40 mg of once daily vorasidenib to standard temozolomide demonstrates acceptable safety in IDH 1/2-mutated gliomas.
Findings from a phase 1b trial show the addition of 40 mg of once daily vorasidenib to standard temozolomide demonstrates acceptable safety in IDH 1/2-mutated gliomas.
Findings from a phase 1b trial...
12/05/2025
Oncology
News
Eflornithine Plus Lomustine Demonstrates Significant Survival Benefit for Molecularly Defined Grade 3 IDH-Mutant Astrocytoma
11/24/2025
Stephanie Holland
Updated molecular analyses from the phase 3 STELLAR trial demonstrated that the combination of eflornithine and lomustine significantly improved survival compared with lomustine alone among patients with grade 3 IDH-mutated astrocytoma.
Updated molecular analyses from the phase 3 STELLAR trial demonstrated that the combination of eflornithine and lomustine significantly improved survival compared with lomustine alone among patients with grade 3 IDH-mutated astrocytoma.
Updated molecular analyses from...
11/24/2025
Oncology
Macarena De La Fuente, MD
Videos
Evaluation of Vorasidenib Plus Temozolomide in IDH1/2-Mutated Glioma
11/22/2025
Macarena De La Fuente, MD
Macarena De La Fuente, MD, discusses results from a phase 1b study that evaluated the safety and tolerability of vorasidenib plus temozolomide in patients with IDH1/2-mutated glioma.
Macarena De La Fuente, MD, discusses results from a phase 1b study that evaluated the safety and tolerability of vorasidenib plus temozolomide in patients with IDH1/2-mutated glioma.
Macarena De La Fuente, MD,...
11/22/2025
Oncology
News
Temozolomide Added to Radiation Significantly Improves Long-Term Survival in IDH-Mutant and 1p/19q-Codeleted Grade 2 Gliomas
11/21/2025
Stephanie Holland
Updated molecular analyses from the phase 3 ECOG-ACRIN E3F05 trial demonstrated that the addition of temozolomide to radiation therapy significantly improved overall survival among patients with grade 2 gliomas.
Updated molecular analyses from the phase 3 ECOG-ACRIN E3F05 trial demonstrated that the addition of temozolomide to radiation therapy significantly improved overall survival among patients with grade 2 gliomas.
Updated molecular analyses from...
11/21/2025
Oncology
News
3D Volumetric RANO Improves Progression Assessment and Correlation for IDH1/2-Mutant Diffuse Glioma: Findings from the Phase 3 INDIGO Trial
11/21/2025
Stephanie Holland
3D volumetric RANO demonstrated stronger treatment effect estimates and improved correlation with clinical outcomes compared with traditional 2D RANO measurements among patients with IDH1/2-mutant diffuse glioma treated with vorasidenib or...
3D volumetric RANO demonstrated stronger treatment effect estimates and improved correlation with clinical outcomes compared with traditional 2D RANO measurements among patients with IDH1/2-mutant diffuse glioma treated with vorasidenib or...
3D volumetric RANO demonstrated...
11/21/2025
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use